Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Gilbert

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 studyMatteo Santoni, Zin W Myint, Thomas Büttner, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII|September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective studyOndřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 studyMatteo Santoni, Zin W Myint, Thomas Büttner, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 studyFrancesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII|September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective studyOndřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Pageof 4